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Natural human tumor necrosis factor beta (TNF./~) purified from supernatants of a human B-lymphoblastoid cell line was found to t~ heteroge- 
neous in molecular mass, with seven components resolved by gel el~trophoresis. All components are N-glyeosylated at Asa~:; N-glycosylation does 
not contribute to heterogeneity, In addition, part of the molecules are O-glycosylated at Thr~; O-glycosylation is heterogeneous due to variable 
decoration with aeuraminie acid. The four lower molecular mass forms are derived from the full-length protein by trypsin-like prot¢olytic cleavage 
in the N~proximal region; these dipped molecules lack O-linked carbohydrates, Two allelic variants differing in amino acid position 26 (threonin~ 
a~paragine) were identified, 
Tumor necrosis Factor beta; Lympho:oxin; Glycosylatinn; Cytokinc 
1, INTRODUCTION 
Tumor necrosis factor beta (TNF-fl), or lympho- 
toxin, is a cytokine produced by activated lymphocytes 
and some B- and T-lymphoid cell lines [1-4]. Human 
TNF-fl is encoded by a gene located on chromosome 6
adjacent o the gene for TNF-0~. The proteins show 29% 
identity in their amino acid sequences; TNF-/~ is longer 
by 17 amino acids at the N-terminal end [5]. Both TNFs 
bind to the same cell surface receptors and show similar 
biological activities~ including cytotoxic or cytostatic 
etI'ects on tumor cells° antiviral activities and a wide 
range of immunomodulatory effects (reviewed in [6,7]). 
TNF-fl is a homotrimeric protein; the subunit con- 
sists of 171 amino acids with a calculated molecular 
mass of 18,664 Da and has a single potential N-glyeosyl- 
ation site [8,10]. Earlier attempts to purify natural 
human TNF-fl from supernatants of lymphoid cell lines 
have resulted in widely varying estimates of molecular 
masses between 12 and >200 kDa [9]. Analysis by SDS- 
PAGE of highly purified preparations also gave incon- 
siste.)tt results, with molecular masses varying between 
20 and 70 kDa [2,10,11]. In several studies, heterogene- 
ous preparations were obtained, with up to seven bands 
with apparent masses between 19 and 80 kDa [12]. Var- 
ious groups, using radiolabelled preparations, provided 
evidence that TNF-fl is N-glycosylated and possibly 
also O-glycosylated [13-i5]. The heterogeneity of some 
preparations thus may be due to post-translational 
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modification. To clarify this situatio,~ and to identify 
the O-glycosylation site(s), we isolated natural TNF-p 
produced by the human B-lymphoblastoid cell line, 
RPMI-1788, and characterized the protein using HPLC 
methods, SDS-PAGE, amino acid sequence analysis 
and deglycosylating enzymes. 
2. MATERIALS AND METHODS 
2.1. Proch~ction a d purification of natural TNF-~ 
TNF-/ff was purified from supernatants of the human B-lympho- 
blastoid cell line. RPMI 1788, stimulated with mezerein by serial 
chromatography on controlled pore glass, Mono Q anion-exchange 
and concanavalin A columns, as described previously [16]. The result- 
in8 material was homogeneous a judged by gel l~rmeation HPLC 
and reverse-phase HPLC. Recombinant, E.colbderived TNF.fl wits 
kindly provided by G. Bodo and by Geaentech Inc., San Fr'aaciseo. 
2.2. SDS-PA OE, HPLC techniques, amino aeM sequence attafysis attd 
peptide mappOtg 
Protein samples were electrophora~¢d in the presence of 0.1% SDS 
on 15% acrylamide gels according to Laemmli [17], Reverse-phase 
HPLC was performed on a Bakerbond WP C18 column (4.6 x 250 
ram, particle s i~ 5 pna, pore diameter 300 A) at 30°C, usin/~ the 
rollowin~ solvents: solvent A, 0, I% trifluoroacetie acid in water;, sol- 
vent B, 0,1% trifluoroacetie acid in acetronitrile. The follow;rig pro- 
gram was used: 0-2 rain, 20% B; 2-26 rain, 20-68% B (linear gradient}; 
26-36 rain, 68% B (flow rate 1 ml/min). Proteins were detected by their 
absorption at 214 and 280 rim. Gel permeation chromatography was 
performed on two Waters Protein-Pak 1 125 connected in series (7.8 
~< 300 mm each, particle size 10/.tin). using 0,:5 M Na2504, 0.02 M 
NaH.~PO~, pH 7.0, 0,04% Tween 20 in 25% propylene glycol (flow rate 
0.5 ml/min). Proteins were detected by their absorption at 214 rim. 
For N-terminal amino acid sequencing, proteins v,,er~ dissolved in 
70% formic acid and directly applied to the cartridge of an Applied 
Biosystems mod=i 477A puled dqui~-phas~ equencer . . . .  e s.que . . . .  
cycles FIL-I, BEGIN-I and NORMAL-I were used as su.~-~ested by 
the manufacturer. The phenylthiohydantoin derivatives of the amino 
Publfshed b), Elsevier Science Fubliz'hers B, V, 85 
Volume 314, number 1 FEBS LETTERS December 1992 
acids from each cycle of the Edman degradation were analyzed on-line 
by reverse-phase HPLC, using an Applied Biosystems model 120A 
instrument. The HPLC con,,itions were chosen according to the rec- 
ommendations of the manut:acturer. Amino acid derivatives were de- 
tect~ by UV absorption at 269 nm. Retention times of the samples 
were compared to a set of st:mdards. 
Peptide maps were generated by treatment of reverse-phase HPLC, 
pt~rifigd protein with trypsin (sequencing grade, Boehringer- 
Mannheim). 100,ug of TNF-fl were dissolved in 100~11% NH4HCO~, 
pH 8.5, and 5,ul trypsin (200/t~/ml in 0.01% trifluoroaeetic a id) were 
added. After incubation for 6 h at 37°C additional 5#1 of trypsin were 
added, and digestion continued for another 18 h at 37°C. Peptides 
were applied to a Merck LiChroCART 125-4 HPLC Cartridge Saper- 
spher 100 RP-18 end-capped column (4 ×119 ram, particle size 4/,tin, 
pore diameter 100 4). Chromatography was performed at 30°C using 
the solvents as described above: parameters: 0-70% B (linear gradi- 
ent), 0-70 rain, I ml/min. Peptides were detected by their absorption 
at 214 ann 280 nm, The resulting maps were compared with a map of 
recombinant E. coli.dgrivgd TNF-/~ prepared similarly. Peptides de- 
rived from natural TNFofl baying no counterpart in the map of the 
recombinant material were sequenced. 
2.3. Degtycosylat:oa 
Deglycosylation experiments were performed with reverse-phase 
HPLC-purified TNF-fl. The protein was dissolved in 50 mM 
CH~COGNa, pH 5.5.4 mM CaCI: and treated with Vibrio choh, rae 
neuraminidase (Boehringgr-Mannheim; 50 mU/ml, 18 h at 37°C). 
Additional treatment with O-glycosidase from Streptococcus pnettt~to- 
nine (Oxford GlycoSystems: 29rnU/ml, 18 h at 37°C) was performed 
in 50 raM Na.,HPOa, 50 mM citric acid, pH 6.0, 0.1% NAN0. N- 
Linked oligosaecharides were cleaved by incubation with N-glycosi- 
dase F l'rom Flavobacteriunt me~Hngosepticttm (Boehringer- 
Mannheim; 140 U/ml, 18 h at 37°C) in 100 mM sodium phosphate, 
pH 8.0, 10 mM EDTA, 0.2% Triton.X-100, 0.1% SDS, 10 mM dithio- 
threitol Ibllowed by reverse-phase HPLC as described above. 
3. RESULTS AND DISCUSSION 
3.1. Polypeptide structure of natural ymphotoxin 
Natural TNF-fl was purified from supernatants of
mezerein-stimulated B-lymphoblastoid cells (cell line 
RPMI 1788) by a series of chromatographic steps as 
described [16]. The resulting material was homogeneous 
as judged by gel permeation HPLC (apparent molecular 
mass, 80 kDa) and by reverse-phase HPLC (data not 
shown). SDS-PAGE, however, revealed heterogeneity 
of the preparation, with five major bands with apparent 
molecular masses of 20.4, 21.1,22.5, 24.3 and 25.2 kDa, 
and two additional, faint bands at 18.6 and 19.8 kDa 
(Fig. 1). The intensity of the four lower molecular mass 
bands varied in different preparations; moreover, we 
observed that their intensity increased upon prolonged 
storage at --20~C, indicating that these bands may rep- 
resent proteolytic leavage products. 
N-terminal sequence analysis (40 cycles) showed a 
single major component (about 85-90% of the total 
protein) corresponding to the expected sequence of the 
full-length protein. Two t'urther components were also 
identified, representing proteolytic leavage products 
lacking the N-terminal 15 and 19 amino acids, respec- 
tively. The cleavage sites correspond to proteolysis by 
a trypsin-li~:e nzyme (Fig. 2); the shortened proteins 







Fig. 1. SDS-PAGE analysis of purified human TNF-fl. Samph,~ were 
separated on a 15% gel, Lanes I and 10, ma~:er proteins (mass scale 
in kDa); lane 2, natural TINF-fl (nTNF-~); lane 3, nTNF-,6 treated 
with neuraminidase; lane 4, nTNF-fl treated with neuraminidase and 
O-glyeosidase; lane 5, nTNF-/~ treated with N-glycosidase F; lane 6, 
oTNF-fl treated with N-glycosidase F and neuraminidase; lane 7, 
nTNF-fl treated with N.81ycosidase F, neuraminidase and O-81ycosi- 
dase; lane 8, recombinant (E. cog.derived) TNF-fl, full length; lane 9, 
recombinant TNF-/L amino acids 24-171. Arrows point to the seven 
bands in the original preparation (lane 2). 
20.4 and 21.1 kDa. The two minor components with 
18.6 and 19.8 kDa were not detectable by this analysis; 
they probably correspond to fragments lacking 28 and 
39 amino acids fl'om the N-terminus (Fig. 2). Note that 
a preparation of recombinant (E. colt-derived, unglyco- 
sylated) TNF-fl also contains proteolytic cleavage prod- 
ucts (Fig. 1, lane 8). 
At position 26 of the full-length protein, two amino 
acids (threonine and asparagine) were identified. Fur- 
ther, sequence analysis of tryptic fragments resolved by 
reverse-phase HPLC identified two peptides with either 
threonine or asparagine in position 26, indicating that 
RPMI 1788 cells express two allelic forms of the TNF-• 
gene. Indeed, analysis of eDNA clones from human cell 
lines [18,19] and genomic DNA clones [20] has previ- 
ously identified sequences coding for both allelic vari- 
ants, differing in a single base (C/A). 
3.2. N- and O-glycosylation 
Analysis of natural TNF-fl by SDS-PAGE after 
cleavage of asparagine-linked carbohydrate residues 
with N-glycosidase F resulted in an increase in electro- 
phoretic mobility of all bands, corresponding to a re- 
duction in molecular mass by about 4 kDa. The overall 
pattern, however, was unchanged, indicating that the 
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I LP~,Cr,%~SA ~QTA~m~ .mA~{STDU@A h.'t,r~PS~O 
41 NSl£~.~.t,rTD RAFL;DDGFSL ~%~SLLVPTS G!YZVY~Q~/q 
81 FSGKAYSPFA TSSPL~q.AHE VQLFSSQYPF HVPLLSSQ~4 
121 VYPGLQEPWL HSMYH~ LTQfNgQ!.STH TDGIPHLVLS 
161 PSTVF=~AFA L 
Fig, 2, Amino acid sequence of human TN F-/5'. Tryptie cleavage sites 
following amino acids 15, 19, 28, 39, 46, 51, 84, 89 and 119. are 
indieatcM by arrows, Sites of O-$1ycos),lation (Thr 7) and N-gl),'cosyla- 
tion (Ash ~') are bold.faced, In position 26. ~wo amino acids were 
identified (asparagine. threonine), 
N-linked carbohydrate moiety does not contribute to 
the heterogeneity (Fig. 1, lanes 2 and 5). Sequence anal- 
ysis of tryptic peptides identifed Ash 62 as the N-glyco- 
sylation site, as e.',,pected from the eDNA sequence (data 
not shown). 
In contrast, treatment of the preparation with neu- 
raminidase affected the mobility of the two upper bands 
only, reducing their mass to result in a single new band 
with 23 kDa (Fig. 1, lanes 2 and 3); additional treatment 
with O-glycosidase resulted in further reduction to 
about 22.5 kDa (lane 4), equivalent to the 22.5 kDa 
band in the original preparation (lane 2) which was 
unaffected by O-glycosidase treatment. This band thus 
most likely corresponds to an N-glycosylated, but not 
O-glycosylated protein. Equivalent changes were seen in 
a preparation that had previously been treated with 
N-glycosidase F (Fig. 1, lanes 5-7). The four low molec- 
ular mass bands of the original preparation correspond- 
ing to N-terminally cleaved proteins were tmafl'ected by 
neuraminidase/O-glycosidase treatment, indicating that 
the O-glycosylation site(s) are located within the 15 N- 
terminal amino acids of the molecule. Indeed, careful 
re-examination f the sequence analysis data revealed 
that the cycle yield of Thr 7 was much lower than ex- 
pected, indicating that this amino acid is modified in 
part of the molecules (data not shown). Further, se- 
quence analysis of tryptic fragments identified both a 
peptide with modified (and therefore undetectable) and 
with unmodified Thr 7. Evidence for farther O-glycosyl- 
ation sites was not obtained. 
Taken together, our results explain the heterogeneity 
of our TNF-Fl preparation as follows. 
(i) Natural human TNF-/3 produced by B-lymphoid 
cells is N-glycosylated at Asn 62. N-Glycosylation does 
not contribute to the observed heterogeneity in molecu- 
lar mass. 
(ii) The majority of full-length molecules i  O-glyco- 
sylated at Thr r (SDS-PAGE bands with masses of 24.3 
and 25.2 kDa); a minor proportion of protein lacking 
O-glycosylatian can be det~ted by SDS-PAGE (22.5 
kDa) and sequence analysis. O-Glycosylation is hetero- 
geneous due to variable decoration of the core carbohy- 
drate by neuraminic acid (probably one and two resi- 
dues, respectively). 
(iii) Additional heterogeneity of the protein is caused 
by trypsin-like proteolytic leavage that removes pep- 
tides from the N-proximal region of the molecules 
(SDS-PAGE bands with masses between 18.6 and 21.1 
kDa). Although proteolysis may be an artefact of the 
purification procedure, these cleavage sites are obvi- 
ously accessible for the protease and may also be recog- 
nized in vivo. TNF-/~ lacking the 23 N-terminal amino 
acids was previously isolated from RPMI 1788 cells 
[10]; this type of cleavage, however, cannot be due to a 
trypsin-like pretense. 
Recent work has elucidated the closely related three- 
dimensional structures of both TNF-0t and TNF-,B [8]. 
In both molecules, the polypeptide chains fold to give 
a compact, bell-shaped trimer composed of,8-pleated 
sheets. The N-terminal ends of the proteins protrude 
from the compact core (10 amino acids in TNF-~z, 27 
in TNF-/3); they apparently do not form well-defined 
structures. It is thus not surprising that the long N- 
terminal end of TNF-/3 is easily accessible to proteolytic 
enzymes, whereas the compact core is highly resistant. 
(iv) Our TNF-]3 preparation does not contain detect- 
able components with a molecular mass higher than 25 
kDa. However, bands that most likely correspond to 
dimers are detectable in samples that were incubated for 
several hours at 37°C during the deglycosylation reac- 
tions (Fig. 1, lanes 3,4,6,7). TNF-/3 components with 
high molecular weight observed by others working with 
iodilmted protein [12] thus most likely also represent 
artefacts of the preparation. 
To explain the heterogeneity of TN F-/3 isolated from 
human lymphoid cells, Rubin et al. [12] have postulated 
that these proteins are encoded by more than one gene. 
However, molecular cloning has so far identified only 
a single TNF-/3 gene in the genomes of humans and 
other mammalian species. The results presented here 
indicate that post-translational modifications of a single 
protein, including variable glycosylation, proteolysis, 
and aggregation, can fully account for the heterogeneity 
of natural TNF-,Fl preparmions. 
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